Cargando…
Efficacy and Safety of Intranasal Esketamine in Patients With Treatment-Resistant Depression and Comorbid Chronic Post-traumatic Stress Disorder: Open-Label Single-Arm Pilot Study
INTRODUCTION: Major depressive disorder (MDD) is more likely to resist to usual treatment when it is associated with post-traumatic stress disorder (PTSD). Capitalizing on the effect of ketamine in both treatment-resistant depression (TRD) and PTSD, we conducted a study in order to assess the effica...
Autores principales: | Rothärmel, Maud, Benosman, Cherifa, El-Hage, Wissam, Berjamin, Caroline, Ribayrol, Diane, Guillin, Olivier, Gaillard, Raphaël, Berkovitch, Lucie, Moulier, Virginie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305073/ https://www.ncbi.nlm.nih.gov/pubmed/35873243 http://dx.doi.org/10.3389/fpsyt.2022.865466 |
Ejemplares similares
-
A prospective multicenter assessor-blinded randomized controlled study to compare the efficacy of short versus long protocols of electroconvulsive therapy as an augmentation strategy to clozapine in patients with ultra-resistant schizophrenia (SURECT study)
por: Moulier, Virginie, et al.
Publicado: (2021) -
Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa
por: Keeler, Johanna Louise, et al.
Publicado: (2023) -
Case report: Intranasal esketamine for severe major depressive disorder with psychotic features
por: Carter, Maximilian, et al.
Publicado: (2022) -
Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review
por: Sapkota, Alisha, et al.
Publicado: (2021) -
Intranasal esketamine as therapeutic option: a case report of an adolescent with treatment resistant depression
por: Skala, Katrin, et al.
Publicado: (2023)